Prelude Therapeutics (PRLD) Competitors $1.22 +0.05 (+4.27%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$1.23 +0.01 (+0.82%) As of 09/25/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRLD vs. PBYI, PRQR, GNFT, AVTE, EPRX, TLSA, SGMT, ACRS, TRDA, and SCLXShould you be buying Prelude Therapeutics stock or one of its competitors? The main competitors of Prelude Therapeutics include Puma Biotechnology (PBYI), ProQR Therapeutics (PRQR), GENFIT (GNFT), Aerovate Therapeutics (AVTE), Eupraxia Pharmaceuticals (EPRX), Tiziana Life Sciences (TLSA), Sagimet Biosciences (SGMT), Aclaris Therapeutics (ACRS), Entrada Therapeutics (TRDA), and Scilex (SCLX). These companies are all part of the "pharmaceutical products" industry. Prelude Therapeutics vs. Its Competitors Puma Biotechnology ProQR Therapeutics GENFIT Aerovate Therapeutics Eupraxia Pharmaceuticals Tiziana Life Sciences Sagimet Biosciences Aclaris Therapeutics Entrada Therapeutics Scilex Puma Biotechnology (NASDAQ:PBYI) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation. Which has preferable valuation and earnings, PBYI or PRLD? Puma Biotechnology has higher revenue and earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPuma Biotechnology$230.50M1.03$30.28M$0.984.80Prelude Therapeutics$7M9.86-$127.17M-$1.64-0.74 Is PBYI or PRLD more profitable? Puma Biotechnology has a net margin of 20.38% compared to Prelude Therapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 53.15% beat Prelude Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Puma Biotechnology20.38% 53.15% 23.51% Prelude Therapeutics N/A -106.50%-79.07% Does the media refer more to PBYI or PRLD? In the previous week, Prelude Therapeutics had 10 more articles in the media than Puma Biotechnology. MarketBeat recorded 13 mentions for Prelude Therapeutics and 3 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 1.75 beat Prelude Therapeutics' score of 1.01 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Prelude Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in PBYI or PRLD? 61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 23.3% of Puma Biotechnology shares are owned by company insiders. Comparatively, 63.9% of Prelude Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, PBYI or PRLD? Puma Biotechnology has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, Prelude Therapeutics has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Do analysts recommend PBYI or PRLD? Puma Biotechnology currently has a consensus price target of $7.00, indicating a potential upside of 48.94%. Prelude Therapeutics has a consensus price target of $4.00, indicating a potential upside of 227.87%. Given Prelude Therapeutics' higher probable upside, analysts clearly believe Prelude Therapeutics is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Prelude Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryPuma Biotechnology beats Prelude Therapeutics on 9 of the 15 factors compared between the two stocks. Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRLD vs. The Competition Export to ExcelMetricPrelude TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.22M$2.55B$5.74B$10.39BDividend YieldN/A54.21%5.75%4.64%P/E Ratio-0.7423.2675.7726.11Price / Sales9.86716.05544.60124.93Price / CashN/A176.2437.5461.24Price / Book0.515.1412.876.30Net Income-$127.17M$32.95M$3.29B$271.03M7 Day Performance23.88%1.15%0.26%-0.14%1 Month PerformanceN/A4.94%2.85%5.82%1 Year Performance-44.80%0.55%65.65%27.63% Prelude Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRLDPrelude Therapeutics3.4047 of 5 stars$1.22+4.3%$4.00+227.9%-41.3%$66.22M$7M-0.74120Trending NewsAnalyst ForecastAnalyst RevisionPBYIPuma Biotechnology4.0117 of 5 stars$4.46+0.9%$7.00+57.0%+84.3%$222.64M$230.50M4.55200Positive NewsPRQRProQR Therapeutics2.4554 of 5 stars$2.16+2.9%$8.00+270.4%+15.0%$220.95M$20.46M-4.70180Positive NewsGNFTGENFIT1.6504 of 5 stars$4.15-4.2%$9.00+116.9%-34.4%$216.51M$76.77M0.00120News CoverageAnalyst ForecastAnalyst RevisionHigh Trading VolumeAVTEAerovate TherapeuticsN/A$7.42-3.8%N/A-88.2%$215.07MN/A-2.4820Positive NewsHigh Trading VolumeEPRXEupraxia Pharmaceuticals2.0685 of 5 stars$6.65+11.6%$11.00+65.4%+125.0%$214.32MN/A-7.8229News CoverageHigh Trading VolumeTLSATiziana Life Sciences0.5874 of 5 stars$1.82flatN/A+120.2%$212.66MN/A0.008News CoverageSGMTSagimet Biosciences3.4278 of 5 stars$6.81+4.4%$25.67+276.9%+163.5%$212.04M$2M-3.728ACRSAclaris Therapeutics2.6103 of 5 stars$1.93+1.0%$8.71+351.5%+67.0%$206.91M$18.72M-1.41100Positive NewsGap DownTRDAEntrada Therapeutics2.7536 of 5 stars$5.28-2.6%$25.67+386.1%-62.9%$206.16M$210.78M-2.97110News CoveragePositive NewsSCLXScilex2.0774 of 5 stars$30.00+3.2%$455.00+1,416.7%+3.1%$202.27M$56.59M-1.0380News Coverage Related Companies and Tools Related Companies Puma Biotechnology Alternatives ProQR Therapeutics Alternatives GENFIT Alternatives Aerovate Therapeutics Alternatives Eupraxia Pharmaceuticals Alternatives Tiziana Life Sciences Alternatives Sagimet Biosciences Alternatives Aclaris Therapeutics Alternatives Entrada Therapeutics Alternatives Scilex Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRLD) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRLD Stock Alerts